Summary
The effect of platelet-activating factor (PAF) was studied during the acute phase of myocardial ischemia in cats. PAF infusion (0.75 μg/kg/h for 4.5 h) in anesthetized, open-chest cat decreased arterial blood pressure, but did not influence heart rate or biochemical indices of cell integrity. The same dose of PAF, however, started 30 min after coronary ligation, resulted in a significantly higher elevation of plasma creatine phosphokinase (CK) activity and a reduced CK content in the region of the ischemic myocardium. Treatment with the thromboxane A2 synthetase inhibitor, CGS-13080, significantly attenuated the PAF-aggravated ischemic cellular damage. These experiments suggest that hypoxiagenerated PAF may contribute to the aggravation of myocardial ischemia, part of which appears to be due to PAF-induced release of thromboxane A2.
Similar content being viewed by others
References
Benveniste J, Henson PM, Cochrane CG (1972) Leukocyte-dependent histamine release from rabbit platelets: the role of IgE-basophils and platelet-activating factor. J Exp Med 136:1356
Benveniste J, Roubin R, Chignard M, Jouvin-Marche E, LeCouedic JP (1982) Release of platelet-activating factor (PAF-acether) and 2-lyso-PAF-acether from three cell types. Agents and Actions 12:711
Benveniste J, Boullet C, Brink C, Labat C (1983) The actions of PAF-acether (platelet-activating factor) on guinea-pig isolated heart preparation. Br J Pharmacol 80:81
Bjork J, Lindbrom L, Gerdin B, Smedegard G, Arfors KE, Benveniste J (1983) PAF-acether (platelet-activating factor) increases microvascular permeability and affects endothelium-granulocyte interaction in microvascular beds. Acta Physiol Scand 119:305
Blank ML, Snyder F, Byers LW, Brooks B, Muirhead EE (1979) Antihypertensive activity of an alkyl ether analog of phosphatidylcholine. Biochem Biophys Res Comm 90:1194
Burke SE, DiCola G, Lefer AM (1983) Protection of ischemic cat myocardium by CGS-13080, a selective potent thromboxane A2 synthesis inhibitor. J Cardiovasc Pharmacol 5:842
Chignard M, LeCouedic JP, Tence M, Vargaftig BB, Benveniste J (1979) The role of platelet-activating factor in platelet aggregation. Nature 279:799
Chignard M, Wal F, Lefort J, Vargaftig BB (1982) Inhibition by sulphinpyrazone of the platelet-dependent bronchoconstriction due to platelet-activating factor (PAF-acether) in the guinea-pig. Eur J Pharmacol 78:71
Coker SJ, Ledingham IMcA, Parratt JR, Zeitlin IJ (1981) Aspirin inhibits the early myocardial release of thromboxane B2 and ventricular ectopic activity following acute coronary artery occlusion in dogs. Br J Pharmacol 72:593
Gorman RR, Morton DR, Hopkins NK, Lin AH (1983) Acetyl glyceryl ether phosphorylcholine stimulates leukotriene B4 synthesis and cyclic AMP accumulation in human polymorphonuclear leukocytes. In: Samuelsson B, Paoletti R, Ramwell P (eds). Adv Prostaglandin, Thromboxane, Leukotriene Res Vol 12. Raven Press, New York, p 57
Lefer AM, Ogletree ML, Smith JB, Silver MJ, Nicolaou KC, Barnette WE, Gasic GP (1978) Prostacyclin: A potentially valuable agent for preserving myocardial tissue in acute myocardial ischemia. Science 200:52
Lefer AM, Polansky EW (1979) Beneficial effects of ibuprofen in acute myocardial ischemia. Cardiology 69:265
Lefer AM, Smith III EF, Araki H, Smith JB, Aharony D, Claremon DA, Magolda RL, Nicolaou KC (1980) Dissociation of vasoconstrictor and platelet aggregatory activities of thromboxane by carbocyclic thromboxane A2, a stable analog of thromboxane A2. Proc Natl Acad Sci USA 7:1706
Lefer AM, Smith JB, Müller HF (1984) Pathophysiologic mechanisms of sudden death induced by platelet-activating factor (PAF). (In Press, Br J Pharmacol)
Leprán I, Koltai M, Szekeres L (1981) Effect of nonsteroid anti-inflammatory drugs in experimental myocardial infarction in rats. Eur J Pharmacol 69:235
McManus LH, Hanahan DJ, Demopoulos CA, Pinckard RN (1980) Pathobiology of intravenous infusion of acetyl glyceryl ether phosphorylcholine (AGEPC), a synthetic platelet-activating factor (PAF), in the rabbit. J Immunol 124:2919
Myers A, Ramey E, Ramwell P (1983) Glucocorticoid protection against PAF-acether toxicity in mice. Br J Pharmacol 79:595
O'Flaherty JT, Wykle RL, Miller CH, Lewis JC, Waite M, Bass DA, McCall CE, DeChatelet LR (1981) 1-0-alkyl-sn-glyceryl-3-phosphorylcholines: a novel class of neutrophil stimulants. Am J Pathol 103:70
Ogletree ML, Lefer AM (1976) Influence of nonsteroidal anti-inflammatory agents on myocardial ischemia. J Pharmacol Exp Therap 197:582
Prevost MC, Cariven C, Simon MF, Chap H, Douste-Blazy L (1984) Platelet activating factor (PAF-acether) is released into rat pulmonary alveolar fluid as a consequence of hypoxia. Biochem Biophys Res Commun 119:58
Rosalki SB (1967) Improved procedure for creatine phosphokinase determination. J Lab Clin Med 69:696
Smith III EF, Lefer AM, Aharony D, Smith JB, Magolda RL, Claremon D, Nicolaou KC (1981) Carbocyclic thromboxane A2: Aggravation of myocardial ischemia by a new synthetic thromboxane A2 analog. Prostaglandins 21:443
Smith JB, Burke SE, Lefer AM, Freilich A (1984) Continuous measurements of ATP secretion in vivo. Pharmaceut Res 1:40
Vargaftig BB, Lefort J, Chignard M, Benveniste J (1980) Platelet activating factor induces a platelet-dependent bronchoconstriction unrelated to the formation of prostaglandin derivatives. Europ J Pharmacol 65:185
Author information
Authors and Affiliations
Additional information
Supported in part by Research Grant No. HL-5565 from the National Heart, Lung and Blood Institute of the NIH.
Rights and permissions
About this article
Cite this article
Leprán, I., Lefer, A.M. Ischemia aggravating effects of platelet-activating factor in acute myocardial ischemia. Basic Res Cardiol 80, 135–141 (1985). https://doi.org/10.1007/BF01910460
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF01910460